ELUTIA INC
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
ELUT$0.93+11.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In Thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Nine Months Ended | ||||||
| · · September 30, | ||||||
| · · 2024 · 2023 | ||||||
| Net loss | | $(44,888) | $(28,342) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | |||||
| Depreciation and amortization | | 2,588 | 2,854 | |||
| Gain on sale of Orthobiologics Business | | (180) | — | |||
| (Gain) loss on revaluation of warrant liability | | 15,321 | (1,070) | |||
| Gain on revaluation of revenue interest obligation | | (1,443) | — | |||
| Amortization of deferred financing costs and debt discount | | 162 | 161 | |||
| Interest expense recorded as additional revenue interest obligation and long-term debt | | 2,086 | 2,473 | |||
| Stock-based compensation | | 6,683 | 1,987 | |||
| Bad debt expense | | | 251 | | | 590 |
| Losses associated with viable bone matrix recall and market withdrawal | | | — | | | 1,984 |
| Changes in operating assets and liabilities: | | | | |||
| Accounts receivable | | 81 | 1,045 | |||
| Inventory | | 220 | (2,490) | |||
| Receivables of litigation costs | | | (1,886) | | | 6,361 |
| Prepaid expenses and other | | 2,171 | 1,609 | |||
| Accounts payable and accrued expenses and payables to tissue suppliers | | (984) | 1,513 | |||
| Contingent liability for legal proceedings | | | 9,265 | | | (1,658) |
| Other liabilities | | 153 | 305 | |||
| Net cash used in operating activities | | (10,400) | (12,678) | |||
| INVESTING ACTIVITIES: | | | ||||
| Proceeds from sale of Orthobiologics Business | | | 180 | | | — |
| Expenditures for property, plant and equipment | | (560) | (329) | |||
| Net cash used in investing activities | | (380) | (329) | |||
| FINANCING ACTIVITIES: | | |||||
| Proceeds from private placement and warrants, net of offering costs of $0.2 million | | | 12,390 | | | 10,335 |
| Repayments of long-term debt | | (2,000) | — | |||
| Proceeds from exercises of Common Warrants and Prefunded Warrants | | | 15,725 | | | — |
| Payments on revenue interest obligation | | (6,300) | — | |||
| Repayments of insurance premium financings | | | (1,721) | | | — |
| Payments for taxes upon vesting of restricted stock units | | | (1,011) | | | (19) |
| Proceeds from stock option exercises and issuance of common stock under ESPP | | 162 | 219 | |||
| Net cash provided by financing activities | | 17,245 | 10,535 | |||
| | | | | | | |
| Net increase (decrease) in cash and cash equivalents | | 6,465 | (2,472) | |||
| | | | | | | |
| Cash and cash equivalents, beginning of period | | 19,276 | 16,989 | |||
| Cash and cash equivalents, end of period | | $25,741 | $14,517 | |||
| | | | | | | |
| Supplemental Cash Flow and Non-Cash Financing Activities Disclosures: | | |||||
| Cash paid for interest | | $4,421 | $1,696 | |||
| Fair value of warrants issued | | $2,464 | | $— | ||
| Operating lease right-of-use asset extensions executed | | $1,379 | | $— | ||
| Conversion of Common Warrants and Prefunded Warrants to common stock | | $17,576 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.